Cerebrovascular Disease in Sickle Cell Anemia

镰状细胞性贫血中的脑血管疾病

• 批准号: 6767335
• 负责人: NORMA B. LERNER
• 金额: $ 11.03万
• 依托单位: UNIVERSITY OF ROCHESTER
• 依托单位国家: 美国
• 财政年份: 2004
• 资助国家: 美国
• 起止时间: 2004-04-01 至 2009-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6767335
• 关键词: aspirin; cerebrovascular disorders; clinical research; clinical trials; cognition disorders; comorbidity; disease /disorder prevention /control; drug screening /evaluation; drug tolerance; human therapy evaluation; longitudinal human study; magnetic resonance imaging; medical complication; middle childhood (6-11); neuropsychological tests; pathologic process; patient oriented research; pediatric pharmacology; preschool child (1-5); sickle cell anemia; statistics /biometry

DESCRIPTION (provided by applicant): Candidate - Dr. Lerner is a pediatric hematologist/oncologist who has recently redirected her focus to patient-oriented investigation. She has completed the course work for an MPH degree and has established working relationships with experienced clinical investigators at the University of Rochester Medical Center. Environment -The Medical Center has the experienced clinical researchers and requisite resources to ensure Dr. Lerner's success. In particular, a Consultant Committee will provide support for this proposal. The Clinical Trials Coordinating Center and Strong Children's Research Center will lend additional expertise. Research - Neurologic complications secondary to cerebrovascular disease are prevalent in children with homozygous sickle cell disease. It is hypothesized that daily low-dose aspirin therapy will safely diminish the incidence and progression of cognitive deficit as well as the predisposition to overt and silent stroke in these children. In order to maximize the design of a future Phase III trial to test this hypothesis, a pilot study has been approved by the NINDS. Its primary objective is to evaluate the safety and tolerability of aspirin. This K24 application proposes additional studies to augment the trial. These will investigate the prognostic relationship of laboratory markers of inflammation and coagulation to the incidence and progression of cerebrovascular damage. Subsequent investigations will evaluate the change secondary to aspirin therapy in those laboratory parameters with prognostic capability. Later proposed studies include investigations regarding magnetic resonance imaging in children with documented stroke on chronic transfusion therapy and tailored educational modifications to improve performance in children with neurocognitive deficits. Mentorship -The principle investigator will provide clinical research training to qualified MDs with a particular interest in pediatric cerebrovascular disease, hemoglobinopathies, and/or neurocognitive function. Trainees will be recruited from: Pediatric Hematology/Oncology fellows, Masters in Public Health (clinical track) candidates, participants in programs of the Department of Neurology, and residents. The program will include core educational instruction, seminar series, and individualized guidance. Trainees will participate in the conduct of the pilot trial and a multi-center phase III study, should this be funded. The additional studies proposed in this application will serve as initial individual clinical research opportunities. Outcome measures will be used to assess the efficacy of the mentoring program.

描述（由申请人提供）：候选人-勒纳博士是一名儿科血液学家/肿瘤学家，她最近将她的重点转向了以患者为导向的研究。她已经完成了公共卫生硕士学位的课程，并与罗切斯特大学医学中心经验丰富的临床研究人员建立了工作关系。